In “New venture fund aims to become the ‘investment and innovation arm’ of the autism community,” TechCrunch tells the story of the Autism Impact Fund (AIF), which is actively fundraising to concentrate financial resources around the science and technology of Autism Spectrum Disorder (ASD). The article features BioROSA Technologies Inc. (IBSF07 2018), which raised more than $3 million this year and is among the AIF portfolio companies. The Boston-based startup is focused on early detection of ASD, developing a biomarker that aims to identify signs of the condition in children as young as 18 months.